CD8A and neoplasm: After treatment with αNKG2A-N215, both tumor-infiltrated granzyme B- and CD25-expressing CD8+ T and NK cells were drastically increased, indicating that αNKG2A-N215 orchestrated both CD8+ T and NK cells to combat tumors.